Development of innovative immunovirotherapy facilitating anti-tumor immunity in bone and soft tissue tumors

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K09653
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56020:Orthopedics-related
• Research Institution: Kagoshima University
• Principal Investigator: Ijichi Nobuhiro 鹿児島大学, 医歯学域医学系, 助教 (80380624)
• Co-Investigator(Kenkyū-buntansha): 小戝 健一郎 鹿児島大学, 医歯学域医学系, 教授 (90258418)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: がん免疫 / 免疫遺伝子ウイルス治療

Outline of Final Research Achievements

Oncolytic viruses (OV) arming immunostimulatory genes are expected to be an innovative immuno-virotherapy. In this study, we developed novel Surv.m-CRAs armed with various soluble immune checkpoint genes and chemokine genes based on our m-CRA technology and verified their in vivo functions. As a result, these oncolytic viruses were revealed to have a tendency to enhance the therapeutic effect and high safety when used in combination with Surv.m-CRAs with other immunostimulatory genes. These results suggest the importance of developing combination immuno-virotherapies using multiple OVs with different therapeutic properties.

Free Research Field

遺伝子治療

Academic Significance and Societal Importance of the Research Achievements

本研究では、次世代の「がん免疫遺伝子・ウイルス治療」の開発へ向け、可溶型免疫チェックポイント遺伝子の搭載戦略の有効性を示し、他の免疫活性化遺伝子搭載ウイルスとの併用による、治療効果増強の可能性を明らかにした。異なる治療作用を有する複数の腫瘍溶解性ウイルスによる、革新的なコンビネーション免疫遺伝子・ウイルス治療開発が難治性がんの根治へとつながることが期待される。